Clearside Bio out-licenses Xipere to Bausch’s B+L

Nano cap Clearside Biomedical (NASDAQ:CLSD) is up 21% premarket on modest volume in reaction to its exclusive license agreement with Bausch Health Companies’ (NYSE:BHC) Bausch + Lomb for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) for the potential treatment of macular edema associated with uveitis.

Under the terms of the deal, Clearside will receive up to $20M prior to market launch, including a $5M upfront payment, up to $56M in milestones and tiered royalties from the high teens to 20% on net sales in the U.S. and Canada.

Bausch Health has the right to pursue additional ophthalmic indications for XIPERE in the U.S. and Canada as well as its SCS Microinjector, in combination with certain corticosteroids and NSAIDs.

Clearside expects to resubmit its U.S. marketing application next quarter. It received a CRL on October 18 citing the need for stability data related to an enhanced manufacturing process.

https://seekingalpha.com/news/3508302-clearside-bio-licenses-xipere-b-l-shares-ahead-21-percent-premarket

Macrogenics down 14% premarket on doubts with margetuximab data

Macrogenics (NASDAQ:MGNX) slips 14% premarket, albeit on only 620 shares, on the heels of updated survival data from a Phase 3 clinical trial evaluating margetuximab in patients with HER2-positive breast cancer.

The combination of the HER2-targeting monoclonal antibody and chemo showed a median increase in overall survival (OS) of 1.8 months (21.6 months vs. 19.8 months) compared to the combination of Roche’s Herceptin + chemo with 11.5% less risk of death (hazard ratio = 0.885). The confidence interval for the hazard ratio, however, was 0.693 – 1.130 with a p value of 0.326, meaning, basically, that treatment with margetuximab may not have improved survival at all.

https://seekingalpha.com/news/3508347-macrogenics-14-percent-premarket-doubts-margetuximab-data

Alexion Pharmaceuticals EPS beats by $0.31, beats on revenue

Alexion Pharmaceuticals (NASDAQ:ALXN): Non-GAAP EPS of $2.79 beats by $0.31; GAAP EPS of $2.08 beats by $0.13.

Revenue of $1.26B (+22.3% Y/Y) beats by $20M.

Press Release

https://seekingalpha.com/news/3508208-alexion-pharmaceuticals-eps-beats-0_31-beats-revenue

Thermo Fisher beats Q3 consensus; guidance raise

Thermo Fisher Scientific (TMO) Q3 results: Revenues: $6,272M (+5.9%); Life Sciences Solutions: $1,701M (+13.1%); Analytical Instruments: $1,358M (+1.9%); Specialty Diagnostics: $879M (-1.7%); Laboratory Products and Services: $2,619M (+6.0%).

Net Income: $760M (+7.2%); EPS: $1.88 (+7.4%); non-GAAP Net Income: $1,187M (+11.4%); non-GAAP EPS: $2.94 (+12.2%); CF Ops: $3,060M (+11.6%).

2019 Guidance: Revenue: $25.34B – 25.50B from $25.30B – $25.50B; Non-GAAP EPS: $12.28 – 12.34 from $12.16 – 12.26.

https://seekingalpha.com/news/3508197-thermo-fisher-beats-q3-consensus-guidance-raised

Lilly EPS beats by $0.07, misses on revenue

Eli Lilly (NYSE:LLY): Q3 Non-GAAP EPS of $1.48 beats by $0.07; GAAP EPS of $1.37 misses by $0.01.

Revenue of $5.48B (+3.2% Y/Y) misses by $20M.

Press Release

https://seekingalpha.com/news/3508202-eli-lilly-eps-beats-0_07-misses-revenue

Thermo Fisher Scientific EPS beats by $0.05, beats on revenue

Thermo Fisher Scientific (NYSE:TMO): Q3 Non-GAAP EPS of $2.94 beats by $0.05; GAAP EPS of $1.88 misses by $0.02.

Revenue of $6.27B (+5.9% Y/Y) beats by $80M.

Press Release

https://seekingalpha.com/news/3508183-thermo-fisher-scientific-eps-beats-0_05-beats-revenue

Anthem EPS beats by $0.05, beats on revenue

Anthem (NYSE:ANTM): Q3 Non-GAAP EPS of $4.87 beats by $0.05; GAAP EPS of $4.55 misses by $0.03.

Revenue of $26.44B (+15.1% Y/Y) beats by $560M.

Press Release

https://seekingalpha.com/news/3508188-anthem-eps-beats-0_05-beats-revenue